Sionna Therapeutics, Inc. SEC filings SION
Sionna Therapeutics, Inc. has 231 filings in SEC EDGAR's recent list, going back to Sep 12, 2024. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 14, 2026 (exit or restructuring costs, officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Other events
|
Sep 14, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| ARS | Annual report to shareholders | Apr 27, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Jun 17, 2026 |
| S-8 | Employee stock plan registration | Mar 2, 2026 | — |
| S-3ASR | Automatic shelf registration | Mar 2, 2026 | — |
| 10-K | Annual report | Mar 2, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 2, 2026 | Mar 2, 2026 |
| 10-Q | Quarterly report | Nov 5, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2025 | Nov 5, 2025 |
| 10-Q | Quarterly report | Aug 11, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 4, 2025 | Jun 4, 2025 |
| 10-Q | Quarterly report | May 12, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 12, 2025 | May 12, 2025 |
| ARS | Annual report to shareholders | Apr 29, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 12, 2025 |
| 10-K | Annual report | Mar 20, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 20, 2025 | Mar 20, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Feb 10, 2025 | Feb 6, 2025 |
| S-8 | Employee stock plan registration | Feb 7, 2025 | — |
| 424B4 | Prospectus | Feb 7, 2025 | — |
| SEC STAFF LETTER | Filing | Feb 6, 2025 | — |
| EFFECT | Filing | Feb 6, 2025 | — |
| S-1MEF | Filing | Feb 6, 2025 | — |
| CERT | Filing | Feb 6, 2025 | — |
| 8-A12B | Filing | Feb 4, 2025 | — |
| CORRESP | Letter to the SEC | Feb 4, 2025 | — |
| CORRESP | Letter to the SEC | Feb 4, 2025 | — |
| S-1/A | Amended registration statement | Feb 3, 2025 | — |
| CORRESP | Letter to the SEC | Jan 24, 2025 | — |
| CORRESP | Letter to the SEC | Jan 17, 2025 | — |
| S-1 | Registration statement | Jan 17, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 10, 2024 | — |
| DRSLTR | Filing | Nov 26, 2024 | — |
| DRS/A | Filing | Nov 26, 2024 | — |
| SEC STAFF LETTER | Filing | Oct 10, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 10, 2024 | — |
| DRS | Filing | Sep 12, 2024 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SION (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2036042
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.